Immunological Subgroups Predicting Efficacy of Elotuzumab in Multiple Myeloma Patients: Insights from the GMMG-HD6 Clinical Trial

Ton, GNHQ; Kriegsmann, K; Awwad, MHS; Benner, A; Bertsch, U; Besemer, B; Hänel, M; Fenk, R; Schlenzka, J; Munder, M; Dürig, J; Blau, IW; Huhn, S; Hose, D; Jauch, A; Neubauer, A; Weinhold, N; Scheid, C; Schroers, R; von Metzler, I; Schieferdecker, A; Thomalla, J; Reimer, P; Mahlberg, R; Graeven, U; Kremers, S; Martens, U; Kunz, C; Hensel, M; Seidel-Glätzer, A; Weisel, K; Salwender, H; Müller-Tidow, C; Raab, MS; Goldschmidt, H; Mai, EK; Hundemer, M

BLOOD, 2023; 142 ():